Z. Paul Lorenc, MD, FACS (pron: Lawrence) is a world-renowned board-certified aesthetic plastic surgeon who balances surgical expertise with an acute aesthetic sense of composition and proportion in the areas of facial rejuvenation, breast enhancement and body contouring.
Since he established his private Park Avenue practice, Dr. Lorenc has been actively involved in the research, development, advancement and creation of new aesthetic surgical and non-surgical techniques and procedures, most notably the endoscopic brow lift and other minimally invasive procedures. Dr. Lorenc’s methods allow for much more precision, are less invasive, limit the risks involved, and, most importantly, provide a more natural result.
Dr. Lorenc is responsible for many patents–one of the most notable is a bio-absorbable soft tissue suspension device, US Patent No. 5,611,814, issued in 1997. The invention of this revolutionary device made procedures less invasive, thereby allowing patients a quicker recovery. It eliminated the need for external metal screws in some procedures, which often required a secondary procedure for removal, and also replaced the use of visible stiches with tiny, nearly undetectable incisions.
Considered an anatomical facial authority, he is a pioneer in the development of the latest generation of dermal fillers and neurotoxins, leading several clinical trials, such as the pivotal study of Restylane®. As the sole aesthetic plastic surgeon involved, Dr. Lorenc headed the largest clinical trial site and tracked the safety and efficacy of Restylane® in a double blind study of more than 100 patients over a twelve-month period. Subsequently, he was selected to lead the team of experts who presented the resulting data on Restylane® to the FDA Advisory Panel, resulting in confirmation for its use in the United States in December 2003. Much more effective and longer lasting than its predecessor, bovine collagen, Restylane® became [and still is] one of the leaders in facial fillers.
Dr. Lorenc is often called upon to appear in front of the FDA in a number of capacities. He has presented data in front of their advisory panels prior to product / drug approval, based on his expertise and the number of patents he holds. He has also appeared and testified on several projects that involve bringing various medical devices through the regulatory process.
Sat. Nov 16
1.30pm –Roundtable on Neuromodulators 4.15pm – Roundtable on Complications